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Abstract
Background: Although significant advances are expected to be made in the assessment of the portal hypertension-related
complications, the prognostic role of spleno-renal shunts has not been fully explored so far. Clarifying this aspect could help
tackle the life-treating events occurring in patients suffering from liver cirrhosis. The aim of the study was to analyze the
relationships between the spleno-renal shunts presence at doppler ultrasound and the liver cirrhosis complications.
Methods: Design: eighty one patients out of 129 formed the study population (35 females). Chronic liver damage in these
patients was caused by HCV (66), HBV (2), alcohol abuse (2) or unknown etiology, likely non-alcoholic steatohepatitis (11).
Setting: two Liver Units of university/primary hospitals in Southern Italy. Main outcome measures: grading of esofageal varices;
detection of ascites: assessment of hepatic encephalopathy; evaluation of liver cirrhosis severity; tracking hepatocellular
carcinoma; doppler features of spleno-renal shunts and splenic flow velocity; spleen longitudinal diameter at sonography.
Results: The prevalence of spleno-renal shunts was 18.5%, without no difference concerning the etiology (HCV versus non-
HCV, p = 0.870); the prevalence of hepatocellular carcinoma in patients with spleno-renal shunts was superior to that of patients
without them (Pearson Chi-square, p = 0.006, power of sample size 74%), also after adjustment for liver decompensation (p =
0.024). The median score of hepatic encephalopathy in patients with and without spleno-renal shunts was similar, i.e., 0 (range,
0-2) versus 0 (0 - 3), p = 0.67. The median splenic vein flow velocity in patients with spleno-renal shunts was significantly inferior
to that of patients without them, i.e., 13 cm/sec (95% confidence intervals, 6-18) versus 21 cm/sec (17-24), p < 0.0001. By far
the largest percentage of large esophageal varices was in patients without spleno-renal shunts (p = 0.005). In contrast, the
frequency of ascites and hepatic encephalopathy severity was overlapping in the two groups. BMI values but not Child-Pugh's
classification predicted spleno-renal shunts (Ors = 1.84, 95% confidence intervals = 1.28-2.64, p = 0.001 and 1.145, 95%
confidence intervals = 0.77-1.51, p = 0.66).
Conclusion: Taking into consideration the relatively small sample size, patients with spleno-renal shunts are burdened by an
increased incidence of hepatocellular carcinoma. BMI predicted the spleno-renal shunts presence.
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Background
The understanding of mechanisms regulating Portal
Hypertension (PH) has been incomplete so far, although
researchers have struggled for years. PH is primarily
caused by an increase in resistance to portal outflow and
secondly by a growth in splanchnic blood flow [1]. In a
later phase, these changes lead to a hyperkinetic circula-
tion that raises cardiac output and reduces systemic vascu-
lar resistance as well as perfusion pressure. Regional
alterations in vasoreactivity (vasodilation and vasocon-
striction), sinusoidal remodelling and capillarization,
angiogenesis, venous thrombosis, and obviously vascular
distortion, all play a certain role in the pathophysiology of
PH by contributing to circulatory impairment and expan-
sion of the collateral circulation. Among vasoactive sub-
stances activated in PH, nitric oxide is considered as the
most important vasodilator. Endothelin-1 and cyclooxy-
genase-derived prostaglandins are the foremost vasocon-
strictor factors, apart from the sympathetic overactivity.
Furthermore, a major role has been attributed to activated
hypercontractile hepatic stellate cells, which cause vascu-
lar remodelling as an adaptive response to the changed
balance in vasoactive substances. It has recently demon-
strated that endothelial dysfunction is determinant in PH
development. Finally, an increase in the splanchnic vascu-
lar bed size mediated by a Vascular Endothelial Growth
Factor (VEGF)-dependent angiogenic process has been
claimed to significantly contribute to increased overall
blood flow in splanchnic tissues of PH animals. In addi-
tion, this VEGF-dependent angiogenesis also plays a cru-
cial role in the formation of portal-systemic collateral
vessels, which include Spleno-Renal shunts (SRS [2]).
Notably, novel research has highlighted that PH is an
independent predictor of HepatoCellular Carcinoma
(HCC) development [3]. Beyond the formation of porto-
systemic shunts, of which Esophageal Varices (EV) have
the greatest clinical impact and the most severe complica-
tions, PH leads to Hepatic Encephalopathy (HE [4]) and
ascites [5]. Other manifestations of PH include portal
hypertensive gastropathy [6] and Large Spontaneous
Shunts (LSS [7]). LSS refer to the presence of patent
paraumbilical vein, SRS, ano-rectosigmoid varices with or
without portal hypertensive colopathy. The prevalence of
umbilical vein patency ranges from 6% to 30% in patients
with PH [8]. SRS are present in cirrhotics from nearly 14%
up to 21% [9,10]. Rectosigmoid varices are present in
nearly one third of cirrhotic patients, 4% of whom have a
lower gastrointestinal hemorrhage [11]. LSS, the presence
of which was assessed by portal venous phase multidetec-
tor-row spiral computed tomography, have been shown
to be responsible for recurrent or persistent HE [12]. In
patients with liver cirrhosis, with and without bleeding
varices, many imaging techniques are available to detect
collaterals, beyond the previously quoted one. In fact,
Magnetic Resonance Imaging (MRI [13]), single photon
emission computed tomography [14,15], selective intra-
arterial digital subtraction angiography [16], scintiphot-
osplenoportography [17], but also the percutaneous tran-
shepatic portography [18], are quite conclusive in
diagnosing SRS. Reports published in the literature to date
have shown that all patients with hepatic cirrhosis should
be studied by using Doppler UltraSound (DUS) tech-
niques [19], being the remainder methods invasive or
extremely expensive and then unsuitable in close follow-
ups. DUS can provide a great deal of information about
the morphology and hemodynamics of PH and conse-
quently spontaneous shunts can be identified [20]. They
may mimic surgically created shunts in their large vol-
ume-flow capacity. In contrast, other Authors believe that
hepato-splenic hemodynamics, as studied at DUS, are
only weakly correlated to portal pressure, suggesting
measuring them with MRI [21]. Anyway, among blood
flow parameters, Splenic Vein Flow Velocity (SVFV) is
considered to be specifically related to the stages of liver
damage [22] and to EV bleeding [23]. Although signifi-
cant advances are expected to be made in the diagnosis
and management of the PH-related complications, in the
face of an increasing burden of chronic liver disease, the
prognostic role of LSS has not been presented in a con-
vincing manner so far. Clarifying this aspect could help
correctly approach the ongoing, life-treating events occur-
ring in patients suffering from liver cirrhosis. Therefore,
the objective of this study was to evaluate the relation of
SRS, detected by an easily reproducible and reliable tool,
i.e., DUS, to the severity of ascites, EV, HE and the pres-
ence of HCC. Furthermore, we intended to seek any asso-
ciation of these imaging parameters with the degree of
liver failure.
Methods
This research was performed screening 129 consecutive
patients with established liver cirrhosis admitted to two
Liver Units of university/primary hospitals in Southern
Italy from October 2006 to December 2008. The study
was carried out according to the principles of the Declara-
tion of Helsinki and an informed written consent was
obtained from each patient.
Exclusion criteria
Out of the initial patients, 23 were excluded because their
instrumental examinations (DUS) had been previously
performed in different centres. Fourteen patients, who
had undergone endoscopic EV ligation therapy, and eight,
who had received beta-blockers, were also disallowed
from the study because prior treatment might have caused
a change in DUS features. Three patients were left out for
the detection of thrombosis of the portal vein.BMC Gastroenterology 2009, 9:89 http://www.biomedcentral.com/1471-230X/9/89
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Inclusion criteria
The remaining 81 patients formed the study population
(35 females) whose age was 68.2, 8.18, 66.4-70 years
(mean, +/-SD, 95% CI). Chronic liver damage in these
patients was caused by hepatitis C (n = 66), hepatitis B (n
= 2), alcohol abuse (n = 2) or unknown etiology, likely
Non-Alcoholic SteatoHepatitis (NASH) (n = 11). Forty
seven patients had compensated cirrhosis of the liver. For
71 patients, the diagnosis of cirrhosis was established by
contextual clinical (spider nevi, hepato-splenomegaly),
laboratory (low serum total cholesterol, prothrombin
activity and pseudocholinesterase levels, reduced white
blood cell and platelets count, globulin/albumin ratio
>1,[24]) as well as antecedent imaging data. Being these
parameters inadequate to confirm the diagnosis in 10
patients, successively assigned to the Child's class A, a liver
biopsy was performed. The non-invasive assessment of
liver cirrhosis was blindly performed de novo to all
patients by experts on the basis of UltraSound (US) and
DUS examinations (coarse echo-texture, nodularity pres-
ence, increased caudate/right lobe ratio, hypertrophy of
the left lobe, characterized by a rounded inferior marginal
edge, and portal vein enlargement with decreased flow
velocity, absence of a normal doppler waveform, hepato-
fugal flow). Alcohol abuse was diagnosed according to the
DSM-IV criteria, by means of screening tests such as MAST
(Michigan Alcohol Screening Test) and CAGE (Cut down,
Annoyed, Guilty, and Eye opener), as well as random tests
for blood alcohol concentration and the use of a surrogate
marker, e.g., Mean Corpuscular Volume.
Prestudy agreement, shared by all the investigators, gave
place to common diagnostic procedures in order to meet
the target of concordance. Patients should have fulfilled
the following criterion at entry, i.e., US/DUS, endoscopic
and laboratory examinations performed within four
weeks of each other.
Endoscopy
EV were graded according to a previous classification, i.e.,
F1 small and straight; F2 moderately sized, tortuous, and
occupying less than one third of the lumen; F3 large,
coiled, and occupying one third or more of the lumen
[25]. Large EV (LEV) were considered F2 and F3.
Ascites presence at ultrasound
The superior end of the right paracolic gutter and the pel-
vis were carefully assessed at US. Small quantities were
sought for around the liver or spleen surface and in the
Morrison's pouch [26]. The presence of peritoneo-pleural
communications was determined. BMI of patients with
ascites was adjusted taking into consideration the weight
before this complication.
Hepatic encephalopathy grade
HE was graded based on the level of consciousness, intel-
lectual functions, behaviour and neuromuscular func-
tions according to West Haven (W-H) criteria [27]. W-H
grade 0 or minimal encephalopathy was ascertained as
previously described [28].
Assessment of liver cirrhosis severity
In all patients the severity of illness was assessed using a
modified Child-Pugh's classification [29], Table 1). The
decompesation criterion was set at score 8 of Child-Pugh's
classification [30], although some patients presented light
ascites or minimal encephalopathy under this cut-off.
Hepatocellular carcinoma detection
Patients were screened for HCC by performing abdominal
US and testing alpha-fetoprotein at admission, in course
of regular 6-monthly or annually (by computed tomogra-
phy) surveillance. When a surveillance feature or test was
abnormal (>10.9 ng/mL), a triple-phase imaging (MRI)
was recommended for evaluation at recall.
Table 1: Child-Pugh classification slightly modified.
Clinic and laboratory data Points for increasing abnormality1
12 3
HE (grade2) None SHE (0), 1-2 3-4
Ascites None at US Mild or controlled by diuretics Present despite diuretics
PT (% of activity)3 > 70 70-40 < 40
Albumin (g/dL) > 3.5 2.8-3.5 < 2.8
Bilirubin (mg/dL) < 2 2-3 > 3
1Scoring system: 5-6 points, grade A; 7-9 points, grade B; 10-15 points, grade C. 2HE: hepatic encephalopathy; Grade 0: sub-clinical hepatic 
encephalopathy, SHE, unravelled by Retain tests A or B; Grade 1: anxiety, irritability, depression, impaired concentration, sleep disturbances; Grade 
2: disorientation, poor short-term memory, disinhibited behavior, drowsiness; Grade 3: somnolence, bizarre behavior, confusion, amnesia, 
paranoia; Grade 4: Coma. 3PT, Prothrombin Time, also expressed in seconds prolonged < 4; 4-6; > 6, or as INR < 1.7; 1.7-2.3; > 2.3. US: 
UltraSound.BMC Gastroenterology 2009, 9:89 http://www.biomedcentral.com/1471-230X/9/89
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Ultrasound and Doppler ultrasound features of spleno-
renalshunts
The SRS detection was based on the following features:
Evidence of tortuous, inferiorly directed vessels from the
splenic hilum to the left kidney (when dealing with the
planes of orientation, i.e., coronal, horizontal, and sagit-
tal, they were primarily seen on the coronal ones);
Splenofugal blood flow [31];
Dilatation of the left renal vein with blood flow phasic
and at high velocity (≥20 cm/sec);
Marked increase of the spleen volume (see below);
Dilatation of the splenic vein diameter (≥5 mm) with
blood flow phasic and at high velocity (SVFV ≥15 cm/sec);
Hepatofugal blood flow in the portal vein
Spleen Longitudinal Diameter (SLD) was performed by
postero-lateral scanning. The Maximum Length (ML, the
optically greatest overall longitudinal dimension
obtained from one of the two poles) and the Cranio-Cau-
dal Length (CCL, the optically maximal transversal
dimension intercepting one of the two poles) were meas-
ured; the resulting values were then averaged, since the
two measurements do not always coincide. SLD, (ML +
CCL/2), ≥150 mm made the spleen be considered defi-
nitely enlarged, being this parameter best correlated to its
size.
Statistics
BMI, SVFV and Child-Pugh's classification values, not nor-
mally distributed (Shapiro-Wilk test, p = 0.001, 0.001 and
0.01), were expressed as median (range). HE, EV and
ascites grades were considered ordinals and managed in
the same way. The difference in medians was assessed by
the Kolmogorov-Smirnov (K-S) Two-Sample test. Age
data, derived from a normally distributed population
(Shapiro-Wilk test, p = 0.44), were articulated as mean
plus SD and 95% confidence intervals (CI); the difference
of means was evaluated by Two-Sample t test. The Two-
Way Tables cross-tabulated one or more than one categor-
ical row variables with one categorical column variable
and the significance was set by the Pearson Chi-square.
When cross-tabulation was stratified for another dichoto-
mous variable the Mantel-Haenszel Chi-square was car-
ried out. The correlation between Child-Pugh's scores and
SVFV values was determined by the Spearman's rho. To
make prediction the logistic regression (Enter method)
was adopted, selecting as independent variable BMI val-
ues as well as the Child-Pugh classification and as depend-
ent variable SRS presence/absence; HE and ascites severity
were not tested in the context of the previous independent
variables to avoid multi-collinearity (situation in which
the predictors are correlated to each other to some
degree). To assess the independent effect of a quantitative
variable, i.e., SFV, on the prediction of the ascites, HE and
EV grades the linear regression analysis (least squares) was
used, evaluating the standardized coefficient beta (β). The
Factor Analysis was applied to detect the structure in the
relationships among variables selecting a subset of varia-
bles, which have the highest correlations with the princi-
pal component factors. The Cattel Scree plot, with relative
eigenvalues, was performed to screen the real factors.
Extraction of the main components amounted to a vari-
ance maximizing (varimax) rotation of the original varia-
ble space. The critical value was calculated by the formula:
doubling the Pearson's correlation coefficient for 1% level
of significance (5.152)/square root of patients minus 2,
i.e., 0.579. The concordance correlation coefficient (ρc),
which measures precision and accuracy, was adopted to
evaluate the degree of pair observations at US. The power
of our sample size was calculated by the non-equality of
proportion with a type I error, alpha, of 0.05. Statistical
analysis was performed operating on Systat 12 (Rich-
mond, CA, USA) and MedCalc Version 11®  (Frank
Schoonjans) software packages.
Results
In order to allow readers to gauge how well the study find-
ings apply to their patients (external validity) we stress
that eighty one patients, divided into two groups of, i.e.,
those with and without SRS, were well balanced in respect
to severity of disease (p = 0.51, Table 2), gender (p = 0.76)
and age (p = 0.98). The median score of W-H criteria in
Table 2: Spleno-renal shunts distribution through liver cirrhosis 
severity.
CHILD Score SRS Absent SRS Present Total
59 1 1 0
61 3 2 1 5
71 6 6 2 2
81 3 1 1 4
97 3 1 0
10 4 0 4
11 3 1 4
12 1 1 2
Total 66 15 81
SRS, Spleno-renal Shunts; Pearson Chi-square, p = 0.51.BMC Gastroenterology 2009, 9:89 http://www.biomedcentral.com/1471-230X/9/89
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patients with and without SRS was similar, i.e., 0 (0-2)
versus 0 (0-3), p = 0.67. The median value of SVFV in
patients without SRS was significantly inferior to that of
patients with SRS, i.e., 13 cm/sec [6-18] versus 21 cm/sec
[17 - 24], p < 0.0001.
Prevalence
The prevalence of SRS in our patients, screened at DUS,
was exactly 18.5% without any difference concerning the
etiology of liver cirrhosis (HCV versus non-HCV, Pearson
Chi-square p = 0.870). Ascites, LEV and HE were present
in 28.3%, 38.3% and 24.7% of our population, respec-
tively. By far the largest percentage of LEV was in patients
without SRS (Pearson Chi-square, p = 0.005, Table 3). In
contrast, the frequency of HE severity and ascites was over-
lapping (Tables 4 and 5). The prevalence of HCC in
patients with SRS was superior to that of patients without
it (Pearson Chi-square, p = 0.006, Table 6), also after
adjustment for liver decompensation (Mantel-Haenszel
Chi-square, p = 0.024). HCC, equally detected on the
basis of the gender (Pearson Chi-square, p = 0.436),
counted for a part (8.6%) of our cohort according to the
expected incidence.
Association
The correlation of the studied DUS parameter, i.e., SVFV,
to the degree of liver failure, weighed by Child-Pugh's
scores was inversely significant (rho = -0.430, p = 0.001).
Interestingly, a hidden correlation was found among the
SLD, the SVFV and the BMI, independently from age of
patients and perhaps of the illness, Figure 1.
Prediction
The estimates of Child-Pugh's classification and BMI val-
ues in predicting the SRS presence gave the following
results: OR = 1.145, 95% CI = 0.77 - 1.51, p = 0.66 and OR
= 1.84, 95% CI = 1.28-2.64, p = 0.001, respectively. Lower
SVFV values predicted more advanced ascites, HE and EV
grades (β = -0.29, p = 0.009; β = -0.37, p = 0.001 and β =
-0.41, p = 0.0001, respectively).
Accuracy
The agreement of US paired observations ranked high,
i.e., ρc = 0.90.
Power analysis
When analysing the impact of the sample size regarding
the HCC presence through the SRS distribution, the
power was 74% with a type I error of 0.05.
Discussion
The essential findings we provide in this study are briefly
i) greater occurrence of HCC in patients with SRS than in
those without them; ii) clear prediction of BMI towards
the SRS presence; iii) detection of fewer LEV in patients
presenting SRS; iiii) same prevalence of ascites and HE
presence in patients with and without SRS. Although
knowledge regarding mechanisms involved in the patho-
genesis of PH has taken unprecedented levels, neverthe-
less many prognostic aspects still remain to be elucidated.
If one considers that knowing them could help better
manage cirrhotic patients, it would then be justifiable to
speculate whether physicians could predict the history of
liver cirrhosis on the basis of the spontaneous SRS pres-
ence by some means. This study aimed at partially answer-
ing this question. The body of present knowledge [9] is in
favour of the fact that the presence of portosystemic col-
laterals identifies cirrhotics with a less favourable clinical
course. Our data only partially agree with this conclusion.
In fact, we provide evidence for a low risk of LEV and a
quite similar prevalence of HE and ascites in patients with
SRS. However, the procrastination of haemorrhagic risk
from LEV in SRS patients would be only temporary,
because the basal critical PH identifies a more severe grade
Table 3: Spleno-renal shunts distribution through large esofageal 
varices presence.
LEV Absent Present Total
SRS Absent 36 30 66
SRS Present 14 1 15
Total 50 31 81
LEV, Large Esofageal Varices; SRS, Spleno-Renal Shunts; Pearson Chi-
square, p = 0.005.
Table 4: Spleno-renal shunts distribution through hepatic 
encephalopathy severity.
HE Grade Absent or Minimal 1 2 3 Total
SRS Absent 50 9 6 1 66
SRS Present 10 4 1 0 15
Total 60 13 7 1 81
SRS, Spleno-Renal Shunts; HE, Hepatic Encephalopathy; Pearson Chi-
square, p = 0. 63.
Table 5: Spleno-renal shunts distribution through ascites 
severity.
Ascites Absent Grade 1 Grade 2 Total
SRS Absent 46 13 7 66
SRS Present 12 2 1 15
Total 58 15 8 81
SRS, Spleno-Renal Shunts; Pearson Chi-square, p = 0.73.BMC Gastroenterology 2009, 9:89 http://www.biomedcentral.com/1471-230X/9/89
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of liver cirrhosis, i.e., very high and long-lasting sinusoi-
dal resistance.
Some of our results are expected if the following is exam-
ined. A recent study comparing Endoscopic Sclerotherapy
(ES) with distal surgical portosystemic shunts in the pre-
vention of recurrent variceal bleeding, has showed that
both these interventions achieved a positive effect on
variceal rebleeding [32]. A switch to decompressive shunt
procedures is mandatory in case of ES or Transjugular Int-
rahepatic Portosystemic Shunt (TIPS) insertion fails to
control recurrent variceal hemorrhage [33]. Selective
shunts are placed surgically to manage post-transplant
portal vein stenosis/thrombosis. In contrast, preexisting
spontaneous portosystemic shunts increase the risk of
post-transplantation portal vein thrombosis [34] and
hamper graft survival [35]. Furthermore, SRS main disad-
vantage is decreased perfusion of the liver with eventually
reduction in liver volume and related function [36]. Nev-
ertheless, surgeons are convinced that the creation of
peripheral portosystemic shunt still has a role in the treat-
ment of some patients with PH on the basis that long-
term blood flow in the portal vein was not severely
reduced after this intervention [37]. Finally, a meta-analy-
sis of individual patient data has provided further evi-
dence that TIPS significantly impacts only on those
patients with the extreme grade of ascites [38], although it
worsens encephalopathy [39]. The novelty of our study
relies on the evidence of an interesting percentage of
patients with SRS in which HCC has been detected,
mainly taking into consideration that HCC prevalence in
our population was lower than that found among Japa-
nese patients (confined to HCV infection), obtained sum-
marizing four representative studies [40], which was 16%
(212/1339). But, how can we explain this major occur-
rence of HCC in them? We emphasize that HCC, the third
leading cause of cancer mortality worldwide, is a highly
vascular tumor that expresses VEGF [41]. An up-to-date
study provides further evidence that obesity increases
HCC risk and that this factor may explain a relevant pro-
portion of cases among subjects in absence of HBV/HCV
infection, probably NASH-mediated [42]. Interestingly,
patients suffering from NASH, a further expression of the
metabolic syndrome, express high serum concentrations
of VEGF [43]. Finally, portal VEGF was significantly
higher than systemic VEGF, and expressions of VEGF and
hepatocyte growth factor in the liver, spleen and intestine
were also up-regulated during liver regeneration [44].
In term of clinical advantage, which take-home lesson
could be drawn from our data? Physicians should try to
strike a balance between pprogressive nutrition deficien-
cies as well as muscle wasting, universal problems in
patients suffering from liver cirrhosis, and a moderately
hypocaloric diet to avoid this eventual risk factor.
As it is repeatedly emphasized, PH remains a partially-
clarified phenomenon and so does the collaterals pres-
ence. Now, the VEGF-dependent angiogenesis is consid-
ered being crucial in determining SRS [2]. A fascinating
hypothesis suggests that portosystemic shunts may mimic
an Arterio-Venous Fistula (A-VF [45]), in which the high-
pressure portal blood relays with the lower pressure sys-
temic venous circulation. Although these collaterals
decompress the portal circulation, the increased cardiac
output enhances portal blood flow and tends to counter-
Table 6: Spleno-renal shunts distribution through hepatocellular 
carcinoma presence
HCC Absent Present Total
SRS Absent 63 3 66
SRS Present 11 4 15
Total 74 7 81
SRS, Spleno-Renal Shunts; HCC, HepatoCellular Carcinoma; Pearson 
Chi-square, p = 0.006.
Factor Loadings Plot Figure 1
Factor Loadings Plot. Body Mass Index, BMI; Spleen Lon-
gitudinal Diameter, SLD; Splenic Vein Flow velocity, SVFV. 
The highest loading is on Factor 2, where three variables are 
strictly correlated.
      
      
                                  Rotated Loading Matrix (VARIMAX) 
 
                                                  1           2           3 
                                --------+----------------------------------- 
                                  BMI       0.077     0.747    -0.308 
                                  SLD      -0.232     0.719     0.367 
                                  SVFV      0.643     0.613     0.005 
                                  CHILD   -0.919     0.124      0.036 
                                  AGE       0.006      0.037     -0.927 
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act the portal hypotensive effect of the portosystemic
shunt. As portal blood flow grows, collateral blood flow
multiplies and is nearly totally shunted in the systemic cir-
culation. Ultimately, high-output cardiac failure occurs
leading to cirrhotic cardiomyopathy. Actually, researchers
demonstrated an over-expression of VEGF in a rabbit A-VF
model [46].
Coming back to the HE detection in both patients with
and without SRS, what does support this finding? In con-
trast with the current opinion, a recent study in patients
with cirrhosis has failed to find a relationship between
EEG alterations and the presence per se of a patent
paraumbilical vein, very common collateral with the same
significance of SRS [7]. Comparing angiographically
patients evidencing LSS and HE with cases characterized
by PH but no HE, Takashi et al. concluded that small SRS
were not associated with HE [47]. On the other hand,
some patients with spontaneous shunts, who had under-
gone shunt reduction by a radiological approach [48],
obtained an amelioration of HE. In conclusion, SRS could
only provide an explanation for the refractoriness of HE.
Continuing on the subject, the lack of association
between liver cirrhosis severity and SRS, found in our
series, is confirmed by the subsequent observations. Fol-
lowing-up consecutive patients with bleeding varices and
LSS, after devascularization with or without esophageal
transaction, the postoperative survival rate of patients
with the LSS was significantly lower than that of patients
without the LSS and preoperative variables concerning
hepatic reserve failed to show significant predictability
[16]. Other data challenge this finding [9]. Discussing the
possible limitations of the present study we have to pin-
point that the sample size of patients with HCC is small,
but it seems to be of sufficient power and adequate to the
low (5%) incidence of this complication in liver cirrhosis
[49]. Moreover, it is correct to evidence that other cutting-
edge technology is more specific for the detection of por-
tosystemic collaterals, e.g., MRI [13]. But, any crucial
future research directions should consider the utility of
DUS particularly when repeated measures are requested
beyond liver transplantation settings [34,35]. Last but not
least consideration, are we sure that splenomegaly is the
consequence of PH and not one of its causes, mainly tak-
ing into consideration the spleno-renal reflex-mediated
reduction in vascular conductance [50] that exacerbates
sodium and water retention in the kidneys?
Conclusion
SRS in liver cirrhosis is a feature more neglected in clinical
practice than among imaging operators. Forecasting
whether the search for SRS would be carried out years
down the line is a dodgy business, because this attitude is
not popular with physicians even though it could influ-
ence the prognostic choices. What will the positive and
negative (in respect to the moderately increased costs)
effects be, it is necessary to ascertain. Anyway, patients
with evidence of SRS are burdened by an enhanced inci-
dence of HCC, mainly if they are overweight or obese. The
awareness of this crucial complication should increase in
order to bring a survival advantage to those patients.
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